Given that the latter study was in discrepant with our findings, which might be due to the different experimental settings, we here investigated the possible mechanism of USP35-FUCA1-mediated oxaliplatin (the third-generation platinum drug) resistance in CRC. Here, FUCA1 is linked to colorectal carcinoma.